This study is in progress, not accepting new patients
Dose Escalation and Dose Expansion Study of CPO-100 in Patients With Advanced Solid Tumors
Summary
- Eligibility
- for people ages 18 years and up (full criteria)
- Location
- at Los Angeles, California and other locations
- Dates
- study startedcompletion around
- Principal Investigator
- by Lee Rosen
Description
Summary
Official Title
Details
Keywords
Eligibility
Locations
Lead Scientist at UCLA
- Lee Rosen
HS Clinical Professor, Medicine. Authored (or co-authored) 113 research publications
Details
- Status
- in progress, not accepting new patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- Conjupro Biotherapeutics, Inc.
- Links
- Phase II study of weekly docetaxel in patients with metastatic breast cancer Metronomics: towards personalized chemotherapy? Dexamethasone differentially depletes tumour and peripheral blood lymphocytes and can impact the efficacy of chemotherapy/checkpoint blockade combination treatment Alpha-1-acid glycoprotein as an independent predictor for treatment effects and a prognostic factor of survival in patients with non-small cell lung cancer treated with docetaxel Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer Taxanes for the treatment of metastatic breast cancer Emerging treatment using tubulin inhibitors in advanced non-small cell lung cancer Phase III trial comparing three doses of docetaxel for second-line treatment of advanced breast cancer Pharmacokinetics and pharmacodynamics of protein-unbound docetaxel in cancer patients Elevated alpha1-acid glycoprotein in gastric cancer patients inhibits the anticancer effects of paclitaxel, effects restored by co-administration of erythromycin Weekly docetaxel in the treatment of metastatic breast cancer A dose finding study of weekly and every-3-week nab-Paclitaxel followed by carboplatin as first-line therapy in patients with advanced non-small cell lung cancer Docetaxel serum protein binding with high affinity to alpha 1-acid glycoprotein A phase I study of liposomal-encapsulated docetaxel (LE-DT) in patients with advanced solid tumor malignancies Annual Report to the Nation on the status of cancer, 1975-2008, featuring cancers associated with excess weight and lack of sufficient physical activity Cancers with increasing incidence trends in the United States: 1999 through 2008 Future of cancer incidence in the United States: burdens upon an aging, changing nation U.S. pancreatic cancer rates Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine Modest improvement in overall survival for patients with metastatic pancreatic cancer: a trend analysis using the surveillance, epidemiology, and end results registry from 1988 to 2008
- ID
- NCT04931823
- Phase
- Phase 1 research study
- Study Type
- Interventional
- Participants
- Expecting 126 study participants
- Last Updated